当前位置:首页 - 行情中心 - 药明康德(603259) - 财务分析 - 现金流量表

药明康德

(603259)

  

流通市值:1707.38亿  总市值:1971.63亿
流通股本:25.01亿   总股本:28.88亿

现金流量表

报告期2025-03-312024-12-312024-09-302024-06-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
销售商品、提供劳务收到的现金10,887,895,827.6241,023,171,534.6929,359,129,012.7119,008,647,246.7
收到的税费返还496,033,127.371,426,098,831.351,312,328,095.051,065,061,541.52
收到其他与经营活动有关的现金256,410,492.71,015,938,369.1575,390,065.07499,205,927.07
经营活动现金流入的平衡项目0000
经营活动现金流入小计11,640,339,447.6943,465,208,735.1431,246,847,172.8320,572,914,715.29
购买商品、接受劳务支付的现金3,720,501,702.7215,075,656,437.510,928,215,498.327,091,223,065.85
支付给职工以及为职工支付的现金3,455,707,702.0710,752,651,632.338,183,330,993.395,831,344,419.11
支付的各项税费669,843,245.53,131,836,919.542,369,175,464.681,937,492,949.89
支付其他与经营活动有关的现金598,856,935.682,098,548,911.181,387,032,831.29746,560,093.07
经营活动现金流出的平衡项目0000
经营活动现金流出小计8,444,909,585.9731,058,693,900.5522,867,754,787.6815,606,620,527.92
经营活动产生的现金流量净额平衡项目0000
经营活动产生的现金流量净额3,195,429,861.7212,406,514,834.598,379,092,385.154,966,294,187.37
二、投资活动产生的现金流量:
收回投资收到的现金2,801,642,393.5411,490,069,612.545,266,733,483.823,159,317,205.94
取得投资收益收到的现金20,004,957.84482,075,411.66242,713,508.52163,095,822.5
处置固定资产、无形资产和其他长期资产收回的现金净额1,678,587.4715,837,544.069,734,408.389,444,507.71
处置子公司及其他营业单位收到的现金净额1,255,520,822.86---
投资活动现金流入的平衡项目0000
投资活动现金流入小计4,078,846,761.7111,987,982,568.265,519,181,400.723,331,857,536.15
购建固定资产、无形资产和其他长期资产支付的现金734,534,627.094,003,492,547.652,491,653,740.121,510,510,362.07
投资支付的现金1,144,555,938.9513,502,667,147.366,221,744,533.733,796,088,510.66
投资活动现金流出的平衡项目0000
投资活动现金流出小计1,879,090,566.0417,506,159,695.018,713,398,273.855,306,598,872.73
投资活动产生的现金流量净额平衡项目0000
投资活动产生的现金流量净额2,199,756,195.67-5,518,177,126.75-3,194,216,873.13-1,974,741,336.58
三、筹资活动产生的现金流量:
吸收投资收到的现金-196,427,943.8816,427,943.8816,427,943.88
取得借款收到的现金4,767,126,048.98,268,427,336.788,265,727,336.785,559,410,201.23
发行债券收到的现金-3,521,497,254.53--
筹资活动现金流入平衡项目0000
筹资活动现金流入小计4,767,126,048.911,986,352,535.198,282,155,280.665,575,838,145.11
偿还债务支付的现金3,408,720,026.728,470,159,769.436,957,913,214.434,197,452,235.42
分配股利、利润或偿付利息支付的现金59,416,181.893,084,876,631.263,049,740,937.382,641,006,578.58
其中:子公司支付给少数股东的股利、利润15,830,160---
支付其他与筹资活动有关的现金62,953,208.744,263,506,782.534,179,385,606.752,199,067,483.46
筹资活动现金流出平衡项目0000
筹资活动现金流出小计3,531,089,417.3515,818,543,183.2214,187,039,758.569,037,526,297.46
筹资活动产生的现金流量净额平衡项目0000
筹资活动产生的现金流量净额1,236,036,631.55-3,832,190,648.03-5,904,884,477.9-3,461,688,152.35
四、汇率变动对现金及现金等价物的影响-61,078,422.61387,525,345.81-9,427,113.53168,611,655.79
现金及现金等价物净增加额平衡项目0000
五、现金及现金等价物净增加额6,570,144,266.333,443,672,405.62-729,436,079.41-301,523,645.77
加:期初现金及现金等价物余额13,444,711,217.6410,001,038,812.0210,001,038,812.0210,001,038,812.02
期末现金及现金等价物余额平衡项目0000
期末现金及现金等价物余额20,014,855,483.9713,444,711,217.649,271,602,732.619,699,515,166.25
补充资料:
净利润-9,567,739,539.18-4,280,845,682.91
资产减值准备-1,236,257,969.76--11,412,652.34
固定资产和投资性房地产折旧-2,372,311,085.1-1,064,715,480.54
其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-2,372,311,085.1-1,064,715,480.54
无形资产摊销-164,533,512.69-83,896,869.39
长期待摊费用摊销-231,657,383.2-116,537,583.71
处置固定资产、无形资产和其他长期资产的损失-36,063,443.51-3,454,353.96
固定资产报废损失-6,234,193.27-2,635,505.76
公允价值变动损失--186,957,574.92-99,587,866.93
财务费用--428,033,421.6--419,747,401.91
投资损失--604,162,381.66--22,379,410.5
递延所得税--44,156,932.49--6,082,318.93
其中:递延所得税资产减少--90,765,548.73--72,874,884.19
递延所得税负债增加-46,608,616.24-66,792,565.26
存货的减少--914,170,842.65--530,209,668.91
经营性应收项目的减少--779,189,585.3-393,964,977.78
经营性应付项目的增加-767,141,307.65--513,977,092.32
其他-366,914,923.65-196,155,788.38
现金的期末余额-13,444,711,217.64-9,699,515,166.25
减:现金的期初余额-10,001,038,812.02-10,001,038,812.02
公告日期2025-04-292025-03-182024-10-292024-07-30
审计意见(境内)标准无保留意见
TOP↑